statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met its primary endpoint and identified a maximum tolerated dose.
read more...

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Q1 2024 EPS Estimates for Revelation Biosciences, Inc. (NASDAQ:REVB) Cut by Zacks Small Cap

Revelation Biosciences, Inc. (NASDAQ:REVB  Free Report)  Stock analysts at Zacks Small Cap dropped their Q1 2024 earnings per share estimates for shares of Revelation Biosciences in a...

Revelation Biosciences (NASDAQ:REVB) Releases Quarterly  Earnings Results, Beats Estimates By $2.61 EPS

Revelation Biosciences (NASDAQ:REVB  Get Free Report) announced its quarterly earnings results on Friday. The company reported ($8.33) earnings per share (EPS) for the quarter, beating the...

Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc.

Revelation Biosciences Inc. (REVB) has disclosed a new risk, in the Regulation category. Revelation Biosciences Inc. faces significant risk due to...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Revelation Biosciences Inc

Volume	19,656.00
52-Wk High	$28.20
52-Wk Low	$1.52

REVB Revelation Biosciences Inc

About

Feed

News

Sentiment

Fundamentals